<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296800</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-454</org_study_id>
    <nct_id>NCT03296800</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Non-Randomized, Fixed-Sequence Composite Study to Evaluate the Effects of Probenecid, Rifampin, and Verapamil on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug-drug interaction in your body when given the
      study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil
      or rifampin. The study will also evaluate how safe the study drug is and how well the study
      drug is tolerated when taken with probenecid, verapamil or rifampin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Actual">December 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax of bexagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of maximum observed plasma concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Tmax of bexagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent terminal elimination half-life)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>T1/2 of bexagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUC0-inf of bexagliflozin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 0-24 hr</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 24-48 hr</measure>
    <time_frame>24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by adverse events</measure>
    <time_frame>Up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin 20 mg, tablet; qd</description>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
    <other_name>EGT0001442, EGT0001474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>Probenecid tablets, 500 mg; bid</description>
    <arm_group_label>Bexagliflozin/probenecid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin, 600 mg (2 x 300 mg capsules); qd</description>
    <arm_group_label>Bexagliflozin/rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Verapamil hydrochloride tablet, 120 mg; qd</description>
    <arm_group_label>Bexagliflozin/verapamil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2

          2. Subjects who have not used tobacco for at least 3 months before screening

          3. Subjects who are willing to use an adequate form of birth control during the study and
             for 30 days after discharge from clinic

          4. Subjects who are willing and able to be confined to the clinical research facility as
             required by the protocol

        Exclusion Criteria:

          1. Subjects with a clinically significant history of allergy to drugs or latex

          2. Subjects with a history of alcohol or drug dependence in the past 12 months.

          3. Subjects who have donated a significant amount of blood in the past 2 months

          4. Female subjects who are pregnant or breastfeeding

          5. Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of
             the investigational drug, whichever is longer

          6. Subjects who had previously taken probenecid, rifampin or verapamil within 3 months of
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

